Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A08472 | 32096890 | Intern Med J | Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. | 2021 | Details |
| A08477 | 32095253 | BMJ Open Gastroenterol | Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). | 2020 | Details |
| A08480 | 32093016 | Cells | The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. | 2020 | Details |
| A08493 | 32087038 | Liver Int | The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. | 2020 | Details |
| A08503 | 32083798 | J Diabetes Investig | Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. | 2020 | Details |
| A08511 | 32081018 | Rev Esp Enferm Dig | Mechanism of bariatric and metabolic surgery: beyond surgeons, gastroenterologists and endocrinologists. | 2020 | Details |
| A08516 | 32077613 | Liver Int | A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. | 2020 | Details |
| A08519 | 32077608 | Liver Int | Natural history of NASH and HCC. | 2020 | Details |
| A08548 | 32065376 | Adv Ther | Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. | 2020 | Details |
| A08552 | 32063885 | Front Endocrinol (Lausanne) | Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. | 2020 | Details |
| A08553 | 32063504 | Ann Hepatol | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? | 2020 | Details |
| A08557 | 32061907 | Metabolism | Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. | 2020 | Details |
| A08566 | 32059982 | J Hepatol | NAFLD as a driver of chronic kidney disease. | 2020 | Details |
| A08582 | 32051820 | Can J Gastroenterol Hepatol | Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. | 2020 | Details |
| A08587 | 32049637 | BMJ Open Diabetes Res Care | Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. | 2020 | Details |
| A08588 | 32048436 | Obes Rev | Foetal and childhood exposure to famine and the risks of cardiometabolic conditions in adulthood: A systematic review and meta-analysis of observational studies. | 2020 | Details |
| A08589 | 32048317 | J Gastroenterol Hepatol | Nonalcoholic fatty liver disease burden: Australia, 2019-2030. | 2020 | Details |
| A08591 | 32047809 | Biomed Res Int | Recombinant Lactococcus lactis Expressing Ling Zhi 8 Protein Ameliorates Nonalcoholic Fatty Liver and Early Atherogenesis in Cholesterol-Fed Rabbits. | 2020 | Details |
| A08597 | 32045507 | Mol Nutr Food Res | Lactose, Maltose, and Sucrose in Health and Disease. | 2020 | Details |
| A08622 | 32039394 | JHEP Rep | Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. | 2019 | Details |
| A08630 | 32039365 | JHEP Rep | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. | 2019 | Details |
| A08634 | 32038102 | Int J Med Sci | Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. | 2020 | Details |
| A08641 | 32033865 | Trends Endocrinol Metab | Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. | 2020 | Details |
| A08677 | 32025167 | J Clin Exp Hepatol | Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. | 2019 | Details |
| A08689 | 32020874 | BMC Complement Med Ther | Zhenqing recipe attenuates non-alcoholic fatty liver disease by regulating the SIK1/CRTC2 signaling in experimental diabetic rats. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A08704 | 32017389 | Diabetes Metab Res Rev | Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. | 2020 | Details |
| A08710 | 32015930 | Liver Res | The acidic pathway of bile acid synthesis: Not just an alternative pathway☆. | 2019 | Details |
| A08716 | 32012908 | Cells | Unraveling LMNA Mutations in Metabolic Syndrome: Cellular Phenotype and Clinical Pitfalls. | 2020 | Details |
| A08735 | 32006558 | Metabolism | Complications, morbidity and mortality of nonalcoholic fatty liver disease. | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A08744 | 32003662 | Curr Pharm Des | Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). | 2020 | Details |
| A08752 | 32000955 | J Am Coll Cardiol | Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. | 2020 | Details |
| A08753 | 32000639 | Curr Pharm Des | Dysmetabolic Iron Overload in Metabolic Syndrome. | 2020 | Details |
| A08754 | 32000567 | Adipocyte | Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. | 2020 | Details |
| A08769 | 31991487 | Hepatology | Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. | 2020 | Details |
| A08774 | 31988860 | Euroasian J Hepatogastroenterol | Nonalcoholic Fatty Liver Diseases among Recently Diagnosed Patients with Diabetes Mellitus and Risk Factors. | 2022 | Details |
| A08788 | 31984787 | Am J Physiol Gastrointest Liver Physiol | Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD. | 2020 | Details |
| A08790 | 31982611 | Clin Gastroenterol Hepatol | Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08842 | 31969089 | Curr Pharm Des | NAFLD at the Interface of the Mother-Infant Dyad. | 2020 | Details |
| A08847 | 31968197 | Endocr Pract | IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. | 2020 | Details |
| A08850 | 31966908 | World J Hepatol | Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. | 2019 | Details |
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | 2020 | Details |
| A08869 | 31956725 | Contemp Clin Trials Commun | Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). | 2019 | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 | Details |
| A08872 | 31955491 | Diabetes Metab Res Rev | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. | 2020 | Details |
| A08886 | 31952573 | Adv Clin Chem | Organokines in disease. | 2019 | Details |
| A08890 | 31950811 | Acta Gastroenterol Belg | Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis. | 2020 | Details |
| A08893 | 31950520 | Hepatology | Nonphagocytic Activation of NOX2 Is Implicated in Progressive Nonalcoholic Steatohepatitis During Aging. | 2020 | Details |
| A08894 | 31949886 | Oxid Med Cell Longev | Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism. | 2019 | Details |
| A08913 | 31941015 | Int J Mol Sci | Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. | 2020 | Details |
| A08916 | 31940026 | Biosci Rep | HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. | 2020 | Details |
| A08918 | 31939698 | AJR Am J Roentgenol | Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08919 | 31937803 | Sci Rep | Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLAdd minipigs. | 2020 | Details |
| A08934 | 31931541 | Z Gastroenterol | A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. | 2020 | Details |
| A08936 | 31930920 | J Med Chem | The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. | 2020 | Details |
| A08948 | 31928475 | Expert Opin Investig Drugs | NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A08973 | 31919793 | Pharmacoeconomics | Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. | 2020 | Details |
| A08982 | 31915709 | J Diabetes Res | Management of Diabetes Mellitus in Patients with Chronic Liver Diseases. | 2019 | Details |
| A08987 | 31914720 | Clin Mol Hepatol | Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. | 2020 | Details |
| A08994 | 31911565 | Anatol J Cardiol | Assessment of left ventricular function in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease using three-dimensional speckle-tracking echocardiography. | 2020 | Details |
| A09009 | 31905727 | Nutrients | Intestinal Fructose and Glucose Metabolism in Health and Disease. | 2019 | Details |
| A09034 | 31897769 | Acta Diabetol | Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. | 2020 | Details |
| A09060 | 33740854 | Vnitr Lek | The role of metabolic syndrome in the induction of chronic pancreatitis after a first attack of acute pancreatitis - multicenter trial. | 2020 | Details |
| A09080 | 31882566 | Diabetes | The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH. | 2019 | Details |
| A09081 | 31882442 | Pharmacol Rev | Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. | 2020 | Details |
| A09083 | 31881781 | Int J Mol Sci | FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. | 2019 | Details |
| A09096 | 31877771 | Cells | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. | 2019 | Details |
| A09108 | 31870938 | Peptides | Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction. | 2019 | Details |
| A09124 | 31866404 | Eur J Pharmacol | Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. | 2019 | Details |
| A09127 | 31865317 | Dig Dis | Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. | 2019 | Details |
| A09133 | 31862937 | Sci Rep | Urinary Levels of Titin-N Fragment, a Skeletal Muscle Damage Marker, are Increased in Subjects with Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09146 | 31858523 | Histol Histopathol | Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype. | 2019 | Details |
| A09157 | 31852748 | J Investig Med | Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. | 2019 | Details |
| A09158 | 31852647 | Nan Fang Yi Ke Da Xue Xue Bao | [Predictive value of body mass index combined with waist circumference for new-onset nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus]. | 2019 | Details |
| A09171 | 31850288 | Front Pediatr | Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease. | 2019 | Details |
| A09180 | 31846507 | Swiss Med Wkly | Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. | 2019 | Details |
| A09186 | 31843573 | J Ethnopharmacol | San-Huang-Tang protects obesity/diabetes induced NAFLD by upregulating PGC-1α/PEPCK signaling in obese and galr1 knockout mice models. | 2019 | Details |
| A09201 | 31838076 | Gastroenterology | Lactotrehalose, an Analog of Trehalose, Increases Energy Metabolism Without Promoting Clostridioides difficile Infection in Mice. | 2019 | Details |
| A09206 | 31836013 | BMC Complement Altern Med | Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. | 2019 | Details |
| A09207 | 31835505 | Nutrients | Weight Gain and De Novo Metabolic Disorders after Liver Transplantation. | 2019 | Details |
| A09213 | 31834465 | Naunyn Schmiedebergs Arch Pharmacol | NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway. | 2019 | Details |
| A09226 | 31829750 | Expert Opin Investig Drugs | Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. | 2019 | Details |
| A09230 | 31827150 | Sci Rep | Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. | 2019 | Details |
| A09233 | 31826068 | J Gastrointestin Liver Dis | Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. | 2019 | Details |
| A09247 | 31819375 | Drug Des Devel Ther | Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways. | 2019 | Details |
| A09257 | 31815784 | Curr Opin Endocrinol Diabetes Obes | Gastrointestinal peptides and nonalcoholic fatty liver disease. | 2020 | Details |
| A09269 | 31810499 | Syst Rev | The impact of environmental cadmium exposure on type 2 diabetes risk: a protocol for an overview of systematic reviews. | 2019 | Details |
| A09270 | 31810110 | Pediatr Obes | Prevalence of prediabetes and type 2 diabetes in children with obesity and increased transaminases in European German-speaking countries. Analysis of the APV initiative. | 2019 | Details |
| A09272 | 31809318 | Chin Med J (Engl) | Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. | 2019 | Details |
| A09280 | 31808097 | Environ Sci Pollut Res Int | Could phthalates exposure contribute to the development of metabolic syndrome and liver disease in humans? | 2019 | Details |
| A09282 | 31806905 | Nat Med | Chronic inflammation in the etiology of disease across the life span. | 2019 | Details |
| A09285 | 31805752 | Molecules | Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models. | 2019 | Details |
| A09292 | 31803542 | PeerJ | Polyphenol-rich Trapa quadrispinosa pericarp extract ameliorates high-fat diet induced non-alcoholic fatty liver disease by regulating lipid metabolism and insulin resistance in mice. | 2019 | Details |
| A09293 | 31803485 | BMJ Open Diabetes Res Care | Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. | 2019 | Details |
| A09296 | 31801616 | J Transl Med | Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. | 2019 | Details |
| A09307 | 31797186 | Dig Dis Sci | Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. | 2019 | Details |
| A09310 | 31795988 | BMC Public Health | First-degree family history of diabetes and its relationship with serum osteocalcin levels independent of liver fat content in a non-diabetic Chinese cohort. | 2019 | Details |
| A09316 | 31793324 | Nutr Hosp | Immunonutritional contribution of gut microbiota to fatty liver disease. | 2020 | Details |